Exelixis Inc Increase (Decrease) in Unbilled Receivables
Exelixis Inc (EXEL) reported Increase (Decrease) in Unbilled Receivables of $32.67 million for the 9-month period ending 2018-09-28, per its 10-Q filed 2018-11-01.
Discontinued › Notes › ASU 2014-09 Transition
us-gaap:IncreaseDecreaseInUnbilledReceivables · last filed 2018-11-01
- Exelixis Inc increase (decrease) in unbilled receivables for the quarter ending 2018-03-30 was $38.01M.
- Exelixis Inc increase (decrease) in unbilled receivables for the quarter ending 2017-03-31 was $0.00.
| Period end | Increase (Decrease) in Unbilled Receivables 3 month | Increase (Decrease) in Unbilled Receivables 9 month |
|---|---|---|
| 2018-09-28 | $32.67M 10-Q · filed 2018-11-01 | |
| 2018-03-30 | $38.01M 10-Q · filed 2018-05-02 | |
| 2017-09-29 | $0.00 10-Q · filed 2018-11-01 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |